BOSTON, June 16, 2016 /PRNewswire/ -- At the
American Society for Microbiology (ASM) Microbe 2016 conference,
Bruker today announces the results of a successful collaboration
with the Special Bacteriology Reference Laboratory at the U.S.
Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia to create an expanded
microorganism reference library for the Bruker MALDI
Biotyper.
This new library, encompassing many rare and emerging pathogens,
is now searchable through MicrobeNet
(https://microbenet.cdc.gov). Developed by the CDC,
MicrobeNet is a database curated by the pathogen subject matter
experts and accessible for all public health and clinical
laboratories. The MALDI Biotyper system
has been rapidly adopted by microbiology laboratories worldwide as
fast and affordable, and as the most comprehensive microbial
identification tool available today, replacing conventional
biochemical and molecular assays. The supplementary microbe
knowledge base generated by the CDC not only provides expanded
capabilities, but access to a wealth of other information and
references for MALDI Biotyper users, from different
parts of the world, in the global public health arena. It will help
researchers identify a wide variety of microbial pathogens more
rapidly in order to better serve public health needs.
The MALDI Biotyper is a microorganism species
identification system based on specific proteomic fingerprints
generated from microbial strains. It is widely used in
microbiology laboratories worldwide due to its proven accuracy,
speed and extensive species coverage. The MALDI
Biotyper research-use-only (RUO) library contains
spectra for over 2,300 species of bacteria and fungi. The
MALDI Biotyper (RUO) also supports an open-library
concept, enabling users to generate customer-defined and validated
libraries to further enhance microorganism coverage. With the
addition of the MicrobeNet MALDI TOF reference library, adding over
800 more species of rare and unusual pathogens, US and
international MicrobeNet users now have direct access to the CDC
library by sending the MALDI Biotyper data and
submitting the search to the CDC MicrobeNet MALDI-TOF library.
John R. McQuiston, Ph.D., Team
Lead, Special Bacteriology Reference Laboratory, Bacterial Special
Pathogens Branch, Division of High-Consequence Pathogens and
Pathology at the CDC, stated: "Our partnership with the diagnostic
testing industry, including Bruker, will lead to greater access to
CDC's MicrobeNet system, and dramatically increase the capabilities
of the public health community using these instruments."
MicrobeNet was launched in 2013 to help US state public health
laboratories and other diagnostic labs rapidly identify rare and
emerging infections, with the goal of saving time, money, and
lives. Funded in part by the CDC's Advanced Molecular
Detection initiative, MicrobeNet currently includes information
about more than 2,400 bacteria and fungi, including images and
information about growing these organisms. Every month, the
CDC adds information on as many as 100 new species to MicrobeNet to
further extend its utility.
George Goedesky, Vice President for Microbiology at Bruker
Daltonics, said: "The public health challenge posed by emerging
pathogens is clear and Bruker is committed to leveraging its
expertise in MALDI-TOF mass spectrometry to address urgent
challenges in the identification of common, as well as of rare and
emerging microorganisms. We are very pleased to have had a
long and productive collaboration with the CDC and other public
health laboratories on identification of bacteria and fungi using
the MALDI Biotyper. The comprehensive
MicrobeNet knowledge base greatly enhances the ability of public
health laboratories to respond more quickly to emerging
pathogens. We are honored to partner with the CDC on the
MicrobeNet project."
About the Bruker MALDI Biotyper
The MALDI Biotyper family of systems enables molecular
identification, and taxonomical classification or de-replication of
microorganisms like bacteria, yeasts and fungi.
Classification and identification of microorganisms is achieved
reliably and quickly using proteomic fingerprinting by
high-throughput MALDI-TOF mass spectrometry. The MALDI
Biotyper uses a molecular approach based on specific proteomic
fingerprints from bacterial strains and published studies have
highlighted the greater accuracy and lower cost offered, as well as
the much faster time-to-result (TTR).
Applications of the various MALDI Biotyper solutions include
clinical routine microbial identification, environmental and
pharmaceutical analysis, taxonomical research, food and consumer
product safety and quality control, as well as marine
microbiology. In many European and international laboratories
the MALDI Biotyper has replaced classical biochemical testing for
bacterial identification in the past seven years due to the
accuracy, speed, extensive species coverage, ease of use and cost
effectiveness of the system. Classical biochemical techniques
detect different metabolic properties of microorganisms, can take
many hours or even days for completion, and they often lack
specificity.
The robust MALDI Biotyper method requires minimal sample
preparation and offers low consumables cost. The products of
the MALDI Biotyper family are available in a research-use-only
(RUO) version, as the U.S. FDA-cleared MALDI Biotyper CA System, or
in an IVD-CE version according to EU directive EC/98/79. The
MALDI Biotyper also has medical device registrations in numerous
other countries. RUO versions of the MALDI Biotyper even
allow selected high-value antimicrobial resistance tests in
translational research.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific research instruments and high-value analytical solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-collaborates-with-cdc-to-advance-infectious-disease-surveillance-300285088.html
SOURCE Bruker Corporation